Wall Street brokerages expect that Citius Pharmaceuticals Inc (NASDAQ:CTXR) will announce ($0.32) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Citius Pharmaceuticals’ earnings. The firm is expected to issue its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Citius Pharmaceuticals will report full year earnings of ($1.43) per share for the current financial year, with EPS estimates ranging from ($1.57) to ($1.28). For the next financial year, analysts forecast that the firm will post earnings of ($0.54) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Citius Pharmaceuticals.
Citius Pharmaceuticals (NASDAQ:CTXR) last released its earnings results on Tuesday, August 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.13.
In related news, insider Myron Z. Holubiak bought 784,314 shares of the firm’s stock in a transaction that occurred on Monday, August 13th. The shares were acquired at an average cost of $1.28 per share, with a total value of $1,003,921.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 52.07% of the stock is currently owned by company insiders.
An institutional investor recently raised its position in Citius Pharmaceuticals stock. Sabby Management LLC boosted its holdings in Citius Pharmaceuticals Inc (NASDAQ:CTXR) by 205.1% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 641,201 shares of the company’s stock after buying an additional 431,070 shares during the period. Citius Pharmaceuticals makes up about 0.2% of Sabby Management LLC’s investment portfolio, making the stock its 16th largest position. Sabby Management LLC owned 6.01% of Citius Pharmaceuticals worth $1,988,000 as of its most recent SEC filing. 3.24% of the stock is owned by hedge funds and other institutional investors.
CTXR opened at $1.59 on Friday. Citius Pharmaceuticals has a 1 year low of $1.12 and a 1 year high of $5.49.
Citius Pharmaceuticals Company Profile
Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido product, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.
See Also: Fundamental Analysis
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.